Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 920 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis C Virus (HCV) Clear all
Completed Phase 3 Interventional Results available

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

NCT03118843
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • Rialto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Not applicable Interventional

Integrated Stepped Care for Unhealthy Alcohol Use in HIV

NCT01410123
View directory record Official record
Conditions
Liver Diseases, Alcoholic, Alcoholism, HIV, Hepatitis C
Interventions
Integrated Stepped Care (ISC), Treatment as Usual
Other
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 15, 2026, 9:01 PM EDT
Not listed Phase 4 Interventional

Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease

NCT02691728
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
LDV/SOF FDC
Drug
Lead sponsor
Peter J. Ruane, M.D., Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

NCT03067129
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Phase 3 Interventional Results available

Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

NCT03092375
View directory record Official record
Conditions
Hepatitis C, HCV
Interventions
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
31
States / cities
Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Phase 2 Interventional Results available

A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

NCT00537407
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Debio 025, Peg-IFNα2a, Ribavirin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
La Jolla, California • Gainesville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Not applicable Interventional

Feasibility of a Hepatitis C Virus (HCV) Decision-Making Intervention Among HIV-infected Adults

NCT01472354
View directory record Official record
Conditions
Hepatitis c
Interventions
Leap-c group intervention
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 15, 2026, 9:01 PM EDT
Active, not recruiting Phase 4 Interventional

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

NCT04508907
View directory record Official record
Conditions
Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
Interventions
Mavyret
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Not applicable Interventional Results available

Intensive Models of HCV Care for Injection Drug Users

NCT01857245
View directory record Official record
Conditions
Hepatitis C, Medication Adherence
Interventions
Intensive Models (mDOT and CGT) of HCV Care
Other
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Phase 2 Interventional Results available

Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients

NCT00018031
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Peginterferon alfa-2b, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Phase 3 Interventional

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

NCT01979939
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV/ASV/BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
42
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 15, 2026, 9:01 PM EDT
Not listed Phase 2 Interventional

12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.

NCT00069511
View directory record Official record
Conditions
Hepatitis C
Interventions
UT-231B
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
6
States / cities
Gainesville, Florida • New Orleans, Louisiana • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

NCT00118768
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
valopicitabine, Pegylated Interferon Alfa
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Timeline
Started 2005
U.S. locations
19
States / cities
Phoenix, Arizona • San Diego, California • San Mateo, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2009 · Synced Oct 15, 2026, 9:01 PM EDT
Completed No phase listed Observational

Anticipated and Perceived Benefits Following Hepatitis C Treatment

NCT03000023
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Phase 4 Interventional Results available

Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

NCT00938860
View directory record Official record
Conditions
Hepatitis C, Liver Transplantation
Interventions
cyclosporin (Neoral), tacrolimus (Prograf)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01225380
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 15, 2026, 9:01 PM EDT
Terminated No phase listed Observational

Hepatitis C in Adults Who Underwent Congenital Heart Surgery Before Screening

NCT00359099
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1980 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 15, 2026, 9:01 PM EDT
Not listed Phase 1 Interventional

Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection

NCT00300807
View directory record Official record
Conditions
Hepatitis C
Interventions
XTL 6865
Drug
Lead sponsor
XTL Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Indianapolis, Indiana • New York, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2007 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Phase 1 Interventional

Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen

NCT00286871
View directory record Official record
Conditions
Chronic Hepatitis C, Organ Transplantation, Immunosuppression
Interventions
Neoral, Tacrolimus
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Phase 4 Interventional Results available

A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C

NCT00394277
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
91
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Phase 3 Interventional

A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

NCT01323244
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years to 99 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Bakersfield, California • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

NCT00931281
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-450, ritonavir, Placebo for ABT-450, Placebo for ritonavir
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 15, 2026, 9:01 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C

NCT01899092
View directory record Official record
Conditions
Hepatitis C
Interventions
TT-034
Drug
Lead sponsor
Tacere Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
San Diego, California • Durham, North Carolina • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 15, 2026, 9:01 PM EDT
Withdrawn Not applicable Interventional

Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Hepatitis C Infection

NCT02070107
View directory record Official record
Conditions
Hepatitis C
Interventions
On Plan
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 15, 2026, 9:01 PM EDT